Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a β-cell line, MIN6 cells

Journal of Atherosclerosis and Thrombosis

Volumn 13, Issue 6, 2006, Pages 329-335

  Ishikawa, Mayumi ^a   Okajima, Fuminori ^b   Inoue, Noriyuki ^a   Motomura, Kaori ^a   Kato, Toyonori ^a   Takahashi, Akimitsu ^a   Oikawa, Shinichi ^b   Yamada, Nobuhiro ^a   Shimano, Hitoshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cholesterol; HMG CoA reductase; Lipotoxicity; SREBP

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN; PRAVASTATIN; PYRROLE DERIVATIVE; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL; ARTICLE; C57BL MOUSE; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; METABOLISM; MOUSE; PANCREAS ISLET BETA CELL; SECRETION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; PRAVASTATIN; PYRROLES; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 38849189665     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13.329     Document Type: Article

References (19)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart' disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344:1383-1389
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, and Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333:1301-1307
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339:1349-1357
4. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, and McCormick LS: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med, 1999; 341:70-76
5. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Jama, 2002; 288:2998-3007
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, and Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361:1149-1158
7. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI Charlton-Menys V, and Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364:685-696
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360:7-22
9. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, and Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 2001; 103:357-362
10. Suzuki M, Kakuta H, Takahashi A, Shimano H, Tada-Iida K, Yokoo T, Kihara R, and Yamada N: Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. J Atheroscler Thromb, 2005; 12:77-84
11. Metz SA, Rabaglia ME, Stock JB, and Kowluru A: Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J, 1993; 295 (Pt 1):31-40
12. 2+ channels in rat islet beta-cells. Br J Pharmacol, 1999; 126:1205-1213
13. Funatsu T, Tanaka H, and Usuda S: Effect of atorvastatin (YM548), a new HMG-CoA reductase inhibitor, on the regulation of cholesterol synthesis in HepG2 cells. Jpn Pharmacol Ther, 1998; 26:1435-1441
14. Scharp DW, Kemp CB, Knight MJ, Ballinger WF, and Lacy PE: The use of ficoll in the preparation of viable islets of langerhans from the rat pancreas. Transplantation, 1973; 16:686-689
15. Amemiya-Kudo M, Oka J, Ide T, Matsuzaka T, Sone H, Yoshikawa T, Yahagi N, Ishibashi S, Osuga J, Yamada N, Murase T, and Shimano H: Sterol regulatory element-binding proteins activate insulin gene promoter directly and indirectly through synergy with BETA2/E47. J Biol Chem, 2005; 280:34577-34589
16. Brown MS and Goldstein JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell, 1997; 89:331-340
17. Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osug, J, Harada K, Gotoda T, Sato R, Kimura S, Ishibashi S, and Yamada N: Transcriptional activities of nuclear SREBP- 1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res, 2002; 43:1220-1235
18. Okajima F, Kurihara M, Ono C, Nakajima Y, Tanimura K, Sugihara H, Tatsuguchi A, Nakagawa K, Miyazawa T, and Oikawa S: Oxidized but not acetylated low-density lipoprotein reduces preproinsulin mRNA expression and secretion of insulin from HIT-T15 cells. Biochim Biophys Acta, 2005; 1687:173-180
19. Takahashi A, Motomura K, Kato T, Yoshikawa T, Nakagawa Y, Yahagi N, Sone H, Suzuki H, Toyoshima H, Yamada N, and Shimano H: Transgenic mice overexpressing nuclear SREBP-1c in pancreatic beta-cells. Diabetes, 2005; 54:492-499